newsfilter
← Latest News
GlobeNewswire·

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received